journal article·2018-11-05Open access

The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells

Hamidreza Javadi, Abbas Sahebghadam Lotfi, Saman Hosseinkhani, Hossein Mehrani, Jafar Amani, Zahra Soheila Soheili, Zahra Hojati, Mehdi Kamali

Abstract

In the present research, we assumed that reducing the amounts of E6 and E7 oncoproteins by a specific siRNA sequence and recovering p53 and RB proteins, along with the recovery of the FOXO1 protein by applying anti-miR-182, would increase apoptosis and reduce proliferation rate in cancer cells. The HPV16-positive CaSki cervical cancer cell line was used. 48 hours after transfection of siRNA for targeting E6 and E7 oncoproteins and anti-miR-182, expression of its cellular targets p53, p21 and FOXO1 was assessed by real-time PCR, western blot analysis and immunocytofluorescence staining. In all treatments, apoptosis rate and viability were evaluated using Annexin-V-FITC apoptosis detection kits and MTT assays, respectively. Among the designed siRNAs, E6-1 and E7-2 proved the most effective in reducing E6 and E7 expressions by increasing the apoptotic rates to 12.4% and 16%, respectively, after 48 hours. Also, using anti-miR-182 increased apoptotic rate to 12.7% 48 hours after transfection of cervical cancer cells. The combinational use of either E6-1 or E7-2 siRNAs with anti-miR-182 resulted in a rise in apoptosis to 19.3% and 26%, respectively, higher than those obtained from the individual application of either without anti-miR-182. The simultaneous use of siRNA E6-1 and siRNA E7-2 with cisplatin increased sensitivity to cisplatin and reduced the viability of the cancer cells as compared to the use of cisplatin alone. The simultaneous use of cisplatin and anti-miR-182 had no considerable effect on viability or apoptosis rate compared to cisplatin alone.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;

Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran;

Department of Clinical Biochemistry, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran;

Department of Biochemistry, Faculty of Basic Sciences, Tarbiat Modares University, Tehran, Iran;

Department of Biochemistry, Faculty of Science, Islamic Azad University Branch of Neyshabur, Neyshabur, Iran;

Applied Microbiology Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Funding

National Institute of Genetic Engineering and Biotechnology

References (51)

Show source-provided references
1. 10.1016/S0929-6646(10)60081-210.1016/S0929-6646(10)60081-2 ↗
2. 10.1128/JVI.63.11.4898-4903.198910.1128/JVI.63.11.4898-4903.1989 ↗
3. 10.1128/JVI.78.21.11451-11460.200410.1128/JVI.78.21.11451-11460.2004 ↗
4. 10.7774/cevr.2014.3.2.16810.7774/cevr.2014.3.2.168 ↗
5. 10.1016/0092-8674(93)90384-310.1016/0092-8674(93)90384-3 ↗
6. 10.1073/pnas.88.13.552310.1073/pnas.88.13.5523 ↗
7. 10.1038/nrd231010.1038/nrd2310 ↗
8. 10.1007/s12038-009-0013-710.1007/s12038-009-0013-7 ↗
9. 10.1038/3504267510.1038/35042675 ↗
10. 10.1126/science.253753210.1126/science.2537532 ↗
11. Boyer SN · Cancer Res · 1996 · 56 · 4620
12. 10.1038/sj.onc.120486010.1038/sj.onc.1204860 ↗
13. 10.1038/onc.2008.35110.1038/onc.2008.351 ↗
14. 10.4143/crt.2005.37.6.31910.4143/crt.2005.37.6.319 ↗
15. 10.1038/sj.cgt.770111810.1038/sj.cgt.7701118 ↗
16. 10.1007/s10495-007-0163-810.1007/s10495-007-0163-8 ↗
17. 10.1038/cgt.2010.3810.1038/cgt.2010.38 ↗
18. 10.1038/nrc199710.1038/nrc1997 ↗
19. 10.1038/nature0617410.1038/nature06174 ↗
20. 10.4238/2015.June.18.310.4238/2015.June.18.3 ↗
21. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
22. 10.1016/0092-8674(93)90500-P10.1016/0092-8674(93)90500-P ↗
23. 10.1016/j.ygyno.2012.12.04310.1016/j.ygyno.2012.12.043 ↗
24. 10.1155/2015/48214610.1155/2015/482146 ↗
25. 10.1038/sj.onc.121091910.1038/sj.onc.1210919 ↗
26. 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R ↗
27. Mahmodabady AZ · Iran Biomed J. · 2010 · 14 · 1
28. 10.1038/nature0287110.1038/nature02871 ↗
29. 10.1007/s10147-013-0526-910.1007/s10147-013-0526-9 ↗
30. 10.3892/ol.2010.17310.3892/ol.2010.173 ↗
31. 10.1016/j.molcel.2005.05.02610.1016/j.molcel.2005.05.026 ↗
32. 10.1038/nrd317910.1038/nrd3179 ↗
33. 10.1038/nature0430310.1038/nature04303 ↗
34. 10.1056/NEJMcibr06006510.1056/NEJMcibr060065 ↗
35. 10.1074/jbc.M115.66867310.1074/jbc.M115.668673 ↗
36. Crook T · Oncogene · 1991 · 6 · 873
37. 10.1093/nar/26.1.20510.1093/nar/26.1.205 ↗
38. 10.1177/193371910629818910.1177/1933719106298189 ↗
39. 10.1038/nrd265610.1038/nrd2656 ↗
40. 10.1038/nrc265710.1038/nrc2657 ↗
41. 10.1002/mc.2045610.1002/mc.20456 ↗
42. 10.1006/scbi.1995.001310.1006/scbi.1995.0013 ↗
43. 10.1158/1535-7163.MCT-13-098210.1158/1535-7163.MCT-13-0982 ↗
44. 10.1002/path.400010.1002/path.4000 ↗
45. 10.1016/j.molcel.2010.12.00510.1016/j.molcel.2010.12.005 ↗
46. 10.1158/0008-5472.CAN-09-189110.1158/0008-5472.CAN-09-1891 ↗
47. 10.1074/jbc.M109.03142710.1074/jbc.M109.031427 ↗
48. Sun J · Int J Clin Exp Pathol · 2015 · 8 · 4755
49. 10.1186/s13073-017-0450-010.1186/s13073-017-0450-0 ↗
50. 10.1080/21691401.2017.130721010.1080/21691401.2017.1307210 ↗
51. 10.1002/ijc.2619710.1002/ijc.26197 ↗